Humacyte, Inc. Other Non-Current Liabilities
Humacyte, Inc. (HUMA) had Other Non-Current Liabilities of $2.09 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-08-12
- 2026-06-30: Other Liabilities, Noncurrent $2.09M.
- 2026-03-31: Other Liabilities, Noncurrent $1.68M.
- 2025-12-31: Other Liabilities, Noncurrent $1.58M.
- 2025-09-30: Other Liabilities, Noncurrent $520.00K.
| Period end | Other Liabilities, Noncurrent | Other Liabilities, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $2.09M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $1.68M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $1.58M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $520.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $984.00K 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $951.00K 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $983.00K 10-K · filed 2026-03-27 | |
| 2024-09-30 | $1.37M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $1.26M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $830.00K 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $711.00K 10-K · filed 2025-03-31 | $789.00K 10-K · filed 2024-03-28 |
| 2023-09-30 | $872.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $890.00K 10-Q · filed 2023-08-14 | |
| 2022-12-31 | $712.00K 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |